Screener
Neurocrine Biosciences NBIX Gross margin
Gross margin at other companies
Other financials
Where this comes from
Calculated from Neurocrine Biosciences’s reported figures.
Based on trailing twelve months.
The source filing: Neurocrine Biosciences’s 10-Q, filed May 5, 2026. Open the filing →
- Filed
- May 5, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000914475-26-000026
FAQ
- What is Neurocrine Biosciences's gross margin?
- Neurocrine Biosciences (NBIX) reported gross margin of 98.2% in Q1 2026.
- How has Neurocrine Biosciences's gross margin changed year-over-year?
- Neurocrine Biosciences's gross margin decreased by 0.4% year-over-year, from 98.5% to 98.2%.
- What is the long-term trend for Neurocrine Biosciences's gross margin?
- Over 5 years (2020 to 2025), Neurocrine Biosciences's gross margin has grown at a -0.2% compound annual growth rate (CAGR), from 99% to 98.2%.
- What does gross margin mean?
- Gross profit (revenue minus cost of revenue) as a percentage of revenue, on a trailing-twelve-month basis. Measures how much of each sales dollar survives the direct cost of producing the goods or services sold.
Ask your AI about Neurocrine Biosciences's gross margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude